Vigil Neuroscience (VIGL) Stock Price, News & Analysis

Company Overview

Vigil Neuroscience is a clinical-stage biopharmaceutical company focused on developing novel therapies to address neuroinflammation in debilitating neurodegenerative diseases. The company’s research centers on the TAM family of receptor tyrosine kinases, which regulate microglial activation and clearance processes in the central nervous system. By modulating these pathways, Vigil aims to slow or halt the progression of conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

Leveraging a proprietary discovery platform, Vigil identifies and optimizes small-molecule modulators with high specificity for TAM receptors and favorable brain penetration. Its lead candidates have demonstrated neuroprotective and anti-inflammatory effects in preclinical models and have progressed into early clinical development. Vigil plans to broaden its pipeline to additional indications where chronic neuroinflammation plays a key role.

Founded in 2019 and headquartered in New York City, Vigil Neuroscience is led by a team of seasoned professionals in neuroscience, drug discovery and clinical development. The company collaborates with academic institutions and industry partners and is supported by venture investors with deep expertise in life sciences, all with the shared goal of delivering transformative therapies for patients living with neurodegenerative disorders.

Key Stats

• Today's Range: $8.05 to $8.05
• 50-Day Range: $7.95 to $8.08
• 52-Week Range: $1.31 to $8.10
• Volume: N/A
• Average Volume: 1.09 million shs
• Market Capitalization: $383.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.80
• Consensus Rating: Hold

VIGL Stock Analysis - Frequently Asked Questions

How were Vigil Neuroscience's earnings last quarter?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04.

When did Vigil Neuroscience IPO?

Vigil Neuroscience (VIGL) raised $112 million in an initial public offering on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share.

What other stocks do shareholders of Vigil Neuroscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vigil Neuroscience investors own include NVIDIA (NVDA), Meta Platforms (META), Exxon Mobil (XOM), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 10/14/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIGL
• CIK: 1827087
• Web: vigilneuro.com
• Phone: 857-254-4445
• Fax: N/A
• Employees: 40
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Vigil Neuroscience: $10.80
• High Price Target: $22.00
• Low Price Target: $8.00
• Potential Upside/Downside: +34.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$84.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -111.70%
• Return on Assets: -74.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.97
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.75 per share
• Price / Book: 4.60

Miscellaneous

• Outstanding Shares: 47,690,000
• Free Float: 39,099,000
• Market Cap: $383.90 million
• Optionable: Not Optionable
• Beta: 3.33